Finally, the fact that inhibitors of NAE1 and FGFR1 pathways had a synergistic effect against SARS-CoV-2 bodes well for using combinations of host-targeted antivirals as well as combining host-targeted antivirals with direct-acting antiviral drugs as a strategy to effectively suppress viral infection and minimize the appearance of drug-resistant mutants from endemic and emerging viral pathogens. This evidence concerns the gene NAE1 and viral infectious disease.